EQT agrees to acquire QIAGEN for approximately €9.6 billion

The provided sources describe a definitive, board-recommended all-cash acquisition agreement between QIAGEN and EQT, making this a material forward-looking merger catalyst rather than a rumor. The valuation is stated as approximately €9.6 billion, or about $10.8 billion; the draft name and description incorrectly expressed the dollar value as euros, so the currency has been corrected. Completion remains conditional on at least 50% plus one share being tendered, shareholder-meeting approvals and regulatory clearances, with closing expected in mid-2027. The occurrence date is explicit, while the exact UTC time is estimated from the first contemporaneous announcement report. The development belongs to existing event 9409 as the definitive milestone following earlier reports of a potential EQT acquisition. Approved stakeholders are limited to the direct target, bidder and the reported competing bidder; broader competitor impacts are too indirect and speculative.